Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gradual Diltiazem Infusion for Rate Control in AF/Flutter
NCT04141553Phase 4Unknown
- Sponsor
- Trinity Health Muskegon
- Start
- Dec 2019
- Primary completion
- Dec 2021
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, double-blind trial of diltiazem in Atrial fibrillation (AFib) and atrial flutter (AFL) (2 arms), sponsored by Trinity Health Muskegon. Primary endpoint: Resolution of arrhythmia at 30 months. Status: unknown.
02
Drugs
diltiazem
03
Conditions
Atrial fibrillation (AFib)atrial flutter (AFL)
Beyond the preview
Go deeper on NCT04141553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04141553.